Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
G. K. Schwartz
No relevant relationships to disclose
R. G. Maki
No relevant relationships to disclose
M. J. Ratain
Research Funding - Bristol-Myers Squibb
S. D. Undevia
No relevant relationships to disclose
R. L. Jones
No relevant relationships to disclose
C. M. Rudin
No relevant relationships to disclose
L. L. Siu
Research Funding - Bristol-Myers Squibb
B. Brockstein
No relevant relationships to disclose
D. Khayat
No relevant relationships to disclose
T. Gil
No relevant relationships to disclose
M. J. De Jonge
No relevant relationships to disclose
M. B. Sawyer
Honoraria - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
T. R. J. Evans
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
J. Medioni
No relevant relationships to disclose
P. J. O'Dwyer
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb (U)
Other Remuneration - Bristol-Myers Squibb
C. Hartman
Employment or Leadership Position - Bristol-Myers Squibb
V. Poulart
Employment or Leadership Position - Bristol-Myers Squibb
I. B. Walters
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb